RESEARCH BY MODUS CREATE X ASCEND2
Healthcare and life sciences AI report: statistics from 119 leaders
Real AI adoption data from 119 product leaders across hospitals, pharma, biotech, and medical device companies. See where AI is actually working in regulated industries, what's blocking scale, and how the highest-performing organizations are pulling ahead.
✓ 13-page PDF ✓ 20+ AI healthcare and life sciences statistics
Key statistics at a glance
What's inside the healthcare and life sciences AI report
This isn't another analyst forecast. It's a complete set of AI adoption statistics, governance frameworks, and regulated industries AI benchmarks from 119 product leaders deploying AI inside hospital systems, pharmaceutical R&D labs, biotech firms, and medical device companies operating under HIPAA, FDA, and GxP requirements.
See how your AI maturity stacks up against 119 healthcare and life sciences organizations across AI adoption rates, ROI timelines, and governance practices in regulated environments.
The 5 questions every leadership team should answer before a single line of code is written, plus the patterns that separate compliant deployments from costly delays.
Where AI delivers ROI within 6 months and where it's quietly burning budget, with adoption rates by AI use case across hospitals, pharma, biotech, and medical device companies.
How top performers are building AI capability without gutting domain expertise, with reskilling versus hiring patterns drawn from our survey of senior product leaders.
4 insights reshaping AI in healthcare and life sciences
We analyzed responses from 119 product leaders to identify the patterns separating organizations scaling AI from those still stuck in pilot. These four insights from the healthcare and life sciences AI report reveal where regulated industries are heading and what it takes to get there ahead of competitors.
INSIGHT 1
Low-risk use cases are quietly winning
While headlines focus on moonshot generative AI projects, the real returns are coming from operational AI use cases. Customer and market research (52%), security and performance monitoring (50%), and quality assurance (45%) lead AI adoption across healthcare and life sciences organizations. Not because they're flashy, but because they deliver measurable value within HIPAA, FDA, and GxP compliance boundaries. The report breaks down where AI is being deployed today and why operational beats experimental in regulated environments.
“Boards and investors aren’t asking how many releases you did this quarter, they’re asking what it delivered.”
INSIGHT 2
AI governance is the #1 reason deployments stall
79% of healthcare and life sciences organizations slowed an AI deployment last year due to unexpected regulatory or ethical considerations. The problem isn't a lack of standards. 51% already have a centralized data governance policy and continuous monitoring dashboards in place. It's that governance is fragmented across compliance, risk, and engineering teams with no single owner. The report maps the shift-left framework that high-performing organizations use to embed governance from day one.
"AI creates new opportunities to trigger actions at speed and scale, which means oversight matters more than ever. Before you deploy, be clear about data access, human decision review, exception handling, and how you’ll evaluate and monitor the quality of AI decisions over time."
INSIGHT 3
Cloud-native AI infrastructure is finally arriving in regulated industries
98% of healthcare and life sciences organizations are modernizing legacy infrastructure, and among them, 53% are planning cloud migration. This isn't aspirational, it's structural. AI workloads demand scalable compute and flexible data architecture that on-premises systems can't deliver. The report details which HCLS-specific cloud services are changing the calculus and how teams maintain validated environments through migration.
INSIGHT 4
The skills gap AI won't close
83% of healthcare and life sciences leaders say execution on strategic product initiatives remains a barrier to success, and AI is making it harder, not easier. Top performers are responding by reskilling existing developers (55%) at twice the rate they're reducing headcount (27%). 96% consider external partners important to product development, particularly for security and compliance specialization (32% cite it as their top focus area). The report shows how teams are restructuring to sustain production-grade AI without losing the domain expertise that makes it valuable.
“Expertise is what makes AI valuable. Without professionals who understand how to build, govern, and apply AI effectively, outcomes quickly become unreliable, insecure, and full of unintended consequences.”
Get the full picture of AI adoption in healthcare and life sciences
The four insights above are just the surface. The full healthcare and life sciences AI report goes deeper into the data, AI governance frameworks, and adoption patterns that separate AI leaders from laggards in regulated industries. Whether you work in hospital systems, pharmaceutical R&D, biotech, or medical devices, the AI statistics show where your organization stands and what it takes to move ahead.
✓ 13-page PDF ✓ 20+ AI healthcare and life sciences statistics
Frequently Asked Questions
Common questions about this healthcare and life sciences AI report, the statistics inside, and the methodology behind the research.